Choosing an immunogen for nanobody discovery means selecting an antigen format that presents the intended target in a biologically relevant way and agreeing on quality controls before production begins. For veterinary medicine projects, that may mean a purified protein, a membrane-associated target, a pathogen-derived antigen, or another format suited to the research question. The best option depends on the target’s structure, the intended nanobody application, and the evidence needed to confirm identity, integrity, and fitness for use. This guide explains the main choices and the questions to resolve with a supplier such as NBbiolab before requesting a proposal.
This guide is intended for veterinary researchers, biotech teams, and procurement specialists planning nanobody discovery against animal proteins, pathogens, or veterinary diagnostic targets. It is also useful when a team has a target sequence but has not yet decided whether a soluble protein, peptide, or cell-based antigen is most appropriate. Buyers comparing custom immunogen preparation services can use the framework to clarify what is included in a quote. It does not replace project-specific advice on animal immunization, biosafety, or regulatory requirements.
Immunogen preparation is the design, production, and quality assessment of antigen material intended to elicit an immune response for downstream binder discovery. The material may be used directly in an immunization workflow or as part of a broader discovery plan, depending on the project design. Its purpose is not simply to provide a protein sample: it must present relevant target features while meeting agreed requirements for handling and analysis. A well-defined preparation plan therefore starts with the intended epitope or application, rather than with a production method alone.
Soluble recombinant proteins are commonly considered when the target domain can be produced in a stable, accessible form. They can be practical for biochemical assays and may offer a defined molecular construct, but truncation, tags, expression host, or missing post-translational modifications can affect how the antigen resembles the native target. Ask for the construct boundaries, expression system, purification approach, and the method used to assess identity and purity. If the final nanobody must recognize the native protein, plan a suitable native-context validation step.
Peptides can be useful when the desired binding region is known, when a linear epitope is the focus, or when full-length protein production is challenging. However, an isolated peptide may not reproduce the shape or accessibility of that sequence in the folded protein. Buyers should confirm peptide sequence, length, terminal modifications, carrier conjugation, and how the conjugate will be distinguished from the target sequence during screening. For a conformational epitope, a peptide alone may be an unsuitable immunogen.
For membrane targets or proteins whose structure depends on a cellular environment, membrane preparations, display systems, or target-expressing cells may better preserve relevant context. These formats can introduce additional variables, including expression level, background components, and batch characterization. For veterinary pathogen targets, a recombinant antigen may be safer and easier to standardize than whole-organism material, but the appropriate choice depends on the target and applicable biosafety controls. Discuss the planned assay format early so the immunogen and screening reagents are not designed in isolation.
For diagnostic development, consider whether the nanobody must recognize the target in serum, tissue, a swab, or another sample matrix. For research reagents, clarify whether binding to purified protein is sufficient or whether recognition of endogenous protein in cells or tissue is required. Veterinary species and strain variation can also matter: a sequence from one species or pathogen isolate may not represent the intended field population. Where cross-reactivity or variant coverage is important, provide relevant sequences or define the species and strains that should be considered.
A useful planning question is: “What result would show that the selected nanobody recognizes the target we care about?” The answer may point to a native-cell assay, a recombinant-protein binding assay, or a test against multiple species variants. This application-first approach helps avoid a mismatch in which an immunogen is technically well characterized but does not support the desired downstream screening. It also helps the supplier identify which controls and antigen formats should be quoted.
With competitive price and timely delivery, NBbiolab sincerely hope to be your supplier and partner.
Request QC appropriate to the material, rather than assuming one panel fits every format. Common items to discuss include identity, concentration, purity, aggregation or integrity, and endotoxin where it is relevant to immunization or downstream use. Depending on the antigen, methods may include sequence or construct confirmation, electrophoretic analysis, chromatography, mass-based analysis, or functional assessment. Ask which methods are available for the proposed material and what the results can—and cannot—demonstrate.
| QC item | Buyer question | Why it matters |
|---|---|---|
| Identity | How is the construct or antigen identity documented? | Confirms that the delivered material corresponds to the agreed target or construct. |
| Purity and integrity | Which method is used, and what acceptance criterion is agreed? | Helps assess contaminants, degradation, or unwanted components. |
| Concentration and quantity | What amount and concentration are required for the planned workflow? | Supports realistic planning for immunization, testing, and repeat use. |
| Endotoxin or functional activity | Is this test relevant to the format and intended use? | Provides project-specific information that may affect material suitability. |
Numerical limits should be agreed for the project, not copied from a generic checklist. For example, a buyer might propose a purity acceptance criterion of at least 90% or an endotoxin limit of no more than 1 EU/mg, but these are illustrative starting points, not universal requirements or a substitute for protocol-specific review. Likewise, concentrations such as 1 mg/mL may be useful to state as a target in a request, but feasibility depends on the protein’s behavior and the proposed formulation. Ask the supplier to identify which requested measurements are available and how any out-of-specification result will be handled.
Provide the target sequence or construct information where possible, along with any available prior expression data, reagents, or assay results. If the target is membrane-bound, glycosylated, unstable, or species-specific, mention this at the outset rather than after production planning. A supplier can then assess whether the requested format and QC plan are feasible or whether alternatives should be considered. Keep a written record of the agreed construct, acceptance criteria, and reporting requirements.
Custom immunogen preparation does not have a universal price, minimum order quantity, or turnaround time. The estimate can depend on antigen complexity, expression system, purification requirements, analytical testing, formulation, and whether development work is needed before a production batch. A soluble construct with established production conditions may have a different scope from a difficult membrane target or a customized cell-based format. Request a project-specific quotation that separates included work, optional tests, material quantity, and any conditions that could change the schedule.
To make supplier proposals easier to compare, ask each provider to state the expected deliverables, QC methods, sample quantity, storage and shipping plan, and any assumptions or exclusions. Clarify whether the quote covers only immunogen preparation or also supports subsequent nanobody discovery steps. Avoid selecting on price alone if the antigen format or documentation differs between proposals. The lowest-cost option may not answer the biological question if it presents the wrong target context.
At NBbiolab, we can discuss immunogen preparation requirements in the context of a nanobody discovery project and help buyers clarify antigen format, QC expectations, and project scope. Share the target details, intended veterinary application, preferred format, and any assay or handling constraints so the proposal can be aligned with the project rather than based on assumptions. Specific feasibility, deliverables, pricing, and timing should be confirmed after review of the target and requested specifications.
The right immunogen preparation service is the one that provides an antigen format suited to the intended nanobody application and a QC plan that makes the delivered material interpretable. Start by defining the target, relevant species or variants, and the assay context, then agree on measurable acceptance criteria and documentation. For the next step, prepare a concise target brief with sequence information, intended use, desired quantity, and any known constraints. Contact NBbiolab to discuss a project-specific immunogen preparation scope and determine which antigen formats and QC items are appropriate.
Want more information on Immunogen Preparation Service for Nanobody Discovery? Feel free to contact us.